CELU — Celularity Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1752828 ·
Last close
$0.57
Market Cap
$18.53M
52W High
$2.55
52W Low
$0.55
ADV30
146,555
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,432,000 | 3,085,000 | -4,237,000 | 706,000 | 96,167,000 | 586,000 | 131,698,000 |
| Mar 2026 | 3,846,000 | 2,394,000 | -10,133,000 | 874,000 | 99,480,000 | 368,000 | 134,741,000 |
| Dec 2025 | 4,104,000 | -3,270,000 | -22,058,000 | -24,362,000 | 107,329,000 | 6,175,000 | 145,391,000 |
| Sep 2025 | 5,284,000 | 1,380,000 | -12,900,000 | -23,076,000 | 114,239,000 | 120,000 | 134,333,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,817,000
Investing CF
$0
Financing CF
$8,987,000
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-2.72
As of
2026-10-25
Balance + Analyst (yfinance extras)
Retained Earnings
$-990,609,000
Inventory
$477,000
Receivables
$4,781,000
ST Investments
—
EBIT TTM
$-66,416,000
Pretax Income TTM
$-71,085,000
Interest Exp TTM
$4,669,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,666,000
EBITDA
$-42,565,000
Free Cash Flow
$-26,285,000
Enterprise Value
$102,916,032
Total Cash
$586,000
Total Debt
$69,833,000
Shares Out
32,449,767
Trailing EPS
$-1.69
Book Value
$-1.21
ROE
—
ROA
-27.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 26,550,000 | -61,308,000 | -91,716,000 | 107,329,000 | 145,391,000 | -38,062,000 | -13,254,000 |
| Dec 2024 | 54,220,000 | -38,551,000 | -57,892,000 | 132,682,000 | 123,845,000 | 8,837,000 | -6,401,000 |
| Dec 2023 | 22,771,000 | -76,479,000 | -196,295,000 | 143,889,000 | 102,929,000 | 40,960,000 | -38,685,000 |
| Dec 2022 | 17,975,000 | -148,267,000 | 14,192,000 | 401,066,000 | 202,165,000 | 198,901,000 | -137,876,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$18,970,000
NetIncome TTM
$-71,088,000
OpCashFlow TTM
—
Assets (Latest)
$99,480,000
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EDSA | Edesa Biotech, Inc. | $18.90M | $1.96 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $18.96M | $1.90 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $17.90M | $0.04 | — |
| LPCN | Lipocine Inc. | $17.72M | $1.60 | — |
| IGC | IGC Pharma, Inc. | $19.43M | $0.19 | — |
News headlines (Yahoo Finance, 1h cache)
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
2026-10-29 13:00 · Yahoo
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
2026-10-22 12:00 · Yahoo
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
2026-09-30 15:57 · Yahoo
Celularity Announces Naveen Jain to Join Board of Directors
2026-09-29 12:30 · Yahoo
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
2026-09-24 13:15 · Yahoo
Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity
2026-08-27 14:27 · Yahoo
Celularity Provides Update Regarding Nasdaq Listing Compliance
2026-08-25 23:59 · Yahoo
NexGel Files to Register 15.25 Million Shares From Note Conversions
2026-08-20 17:35 · Yahoo
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
2026-05-01 20:30 · Yahoo
Celularity Receives Nasdaq Notice Regarding Form 10-Q
2026-05-29 21:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.